Dienogest: a new therapeutic agent for the treatment of endometriosis.

@article{Harada2010DienogestAN,
  title={Dienogest: a new therapeutic agent for the treatment of endometriosis.},
  author={Tasuku Harada and Fuminori Taniguchi},
  journal={Women's health},
  year={2010},
  volume={6 1},
  pages={27-35}
}
Dienogest (DNG), a progestin of 19-nortestosterone derivative, has good oral bioavailability and is highly selective for progesterone receptors. Owing to its antiovulatory, antiproliferative activities in endometrial cells, and its inhibitory effects on the secretion of cytokines, DNG is expected to be an effective treatment for endometriosis. Progesterone receptor-binding affinity is higher for DNG than for progesterone. Several pilot studies demonstrated that after 24 weeks of DNG treatment… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Several pilot studies demonstrated that after 24 weeks of DNG treatment , there was a significant decrease in terms of dysmenorrhea , premenstrual pain , dyspareunia and diffuse pelvic pain .
Several pilot studies demonstrated that after 24 weeks of DNG treatment , there was a significant decrease in terms of dysmenorrhea , premenstrual pain , dyspareunia and diffuse pelvic pain .
Several pilot studies demonstrated that after 24 weeks of DNG treatment , there was a significant decrease in terms of dysmenorrhea , premenstrual pain , dyspareunia and diffuse pelvic pain .
Good efficacy and tolerability of DNG in patients with endometriosis have been demonstrated in an open , randomized European clinical trial as compared with norethisterone acetate .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Most of the cases of genital bleeding occurring in the DNG treatment were spotting or breakthrough bleeding , which decreased with continued treatment and resolved either during treatment or after the end of treatment .
Dienogest ( DNG ) , a progestin of 19-nortestosterone derivative , has good oral bioavailability and is highly selective for progesterone receptors .
Dienogest ( DNG ) , a progestin of 19-nortestosterone derivative , has good oral bioavailability and is highly selective for progesterone receptors .
All Topics